HCW Biologics (NASDAQ:HCWB) Stock Price Down 0.7% – What’s Next?

Shares of HCW Biologics Inc. (NASDAQ:HCWB) traded down 0.7% during mid-day trading on Monday . The company traded as low as $4.19 and last traded at $4.32. 23,008 shares changed hands during trading, a decline of 92% from the average session volume of 281,697 shares. The stock had previously closed at $4.35.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Maxim Group lowered their price target on HCW Biologics from $120.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, May 29th. Wall Street Zen upgraded HCW Biologics from a “sell” rating to a “hold” rating in a research report on Sunday, June 22nd.

HCW Biologics Stock Down 0.7%

The company has a market cap of $6.22 million, a PE ratio of -0.19 and a beta of 0.65. The business has a 50-day simple moving average of $6.08 and a 200-day simple moving average of $10.56.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share for the quarter.

Insider Activity at HCW Biologics

In related news, SVP Lee Flowers purchased 962 shares of the business’s stock in a transaction that occurred on Thursday, May 8th. The stock was purchased at an average price of $26.00 per share, with a total value of $25,012.00. Following the completion of the acquisition, the senior vice president owned 5,720 shares in the company, valued at $148,720. This trade represents a 20.22% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Rebecca Byam purchased 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 8th. The stock was bought at an average cost of $26.00 per share, with a total value of $220,012.00. Following the acquisition, the chief financial officer owned 43,010 shares of the company’s stock, valued at approximately $1,118,260. The trade was a 24.49% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 11,732 shares of company stock valued at $305,032. 42.70% of the stock is currently owned by insiders.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.